Haleon (HLN) Gross Margin (2021 - 2023)

Haleon (HLN) posted Gross Margin of 61.69% for Q4 2023, down 0.72% on a QoQ basis from 62.14% in Q2 2023, and down 12978.0% year-over-year from N/an in Q4 2022.

Haleon (HLN) Gross Margin (2021 - 2023) Analysis & Trends

Haleon's Gross Margin history runs 3 years deep, the most recent figure standing at 61.69% for Q4 2023.

  • Quarterly Gross Margin fell 12978.0% year-over-year to 61.69% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 81.01% (changed N/A YoY) and the FY2025 annual result came in at 64.19%, up 344.0% from the prior year.
  • Gross Margin was 61.69% for Q4 2023 at Haleon, down from 62.14% in the prior quarter.
  • Across five years, Gross Margin topped out at 191.47% in Q4 2022 and bottomed at 61.62% in Q2 2023.
  • A 3-year average of 87.76% and a median of 61.87% in 2021 frame the typical range for Gross Margin.
  • Annual changes were most pronounced in 2022 — Gross Margin jumped 12960 bps — and 2023, when it slumped 12978 bps.
  • Haleon's Gross Margin stood at 61.87% in 2021, then surged by 209 bps to 191.47% in 2022, then plunged by 68 bps to 61.69% in 2023.
  • Business Quant data shows HLN's Gross Margin at 61.69% in Q4 2023, 62.14% in Q2 2023, and 61.62% in Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 49.52%
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 71.66%
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 62.93%
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 82.93%
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 32.97%
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 98.31%
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 57.26%
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn 55.84%

Historic Data

Download Data
DateValue
Dec 31, 2023 61.69%
Jun 30, 2023 62.14%
May 3, 2023 61.62%
Dec 31, 2022 191.47%
Dec 31, 2021 61.87%